martes, 22 de septiembre de 2020

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov

STAT China

Jonathan Chan

Chinese vaccine maker to extend trial to teenagers, children

Sinovac Biotech plans to test its experimental Covid-19 vaccine on younger subjects in a new trial, Reuters reported.

The company is looking to recruit 552 subjects between 3 and 17 years old to receive two shots of either a placebo injection or CoronaVac, Sinovac’s inactivated vaccine in the new Phase 1/2 study that is slated to begin at the end of this month.

Beijing-based Sinovac is only one of a handful of Chinese companies racing to develop a Covid-19 vaccine. CoronaVac is already in Phase 3 testing in several countries, such as Brazil and Indonesia. The company also recently revealed that a large majority of its own employees and their family have taken its vaccine.

No hay comentarios: